Cart
sales@molnova.com
JAK-IN-11
CAS No. 916742-11-5
JAK-IN-11( R-348 )
Catalog No. M26394 CAS No. 916742-11-5
JAK-IN-11 is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 644 | In Stock |
|
| 5MG | 568 | In Stock |
|
| 10MG | 923 | In Stock |
|
| 25MG | 1682 | In Stock |
|
| 50MG | 2213 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJAK-IN-11
-
NoteResearch use only, not for human use.
-
Brief DescriptionJAK-IN-11 is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.
-
DescriptionJAK-IN-11 is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.(In Vitro):JAK/STAT signaling has been implicated in the mediation of many abnormal immune responses such as allergies, asthma, autoimmune diseases such as transplant rejection, rheumatoid arthritis, amyotrophic lateral sclerosis and multiple sclerosis, ocular disorders and diseases, as well as in solid and hematologic malignancies such as leukemia and lymphomas.
-
In VitroJAK kinases are a family of cytoplasmic protein tyrosine kinases including JAK1, JAK2, JAK3 and TYK2. STAT proteins function both as signaling molecules and transcription factors and ultimately bind to specific DNA sequences present in the promoters of cytokine-responsive genes. JAK/STAT signaling has been implicated in the mediation of many abnormal immune responses such as allergies, asthma, autoimmune diseases such as transplant rejection, rheumatoid arthritis, amyotrophic lateral sclerosis and multiple sclerosis, ocular disorders and diseases, as well as in solid and hematologic malignancies such as leukemia and lymphomas.
-
In Vivo——
-
SynonymsR-348
-
PathwayAngiogenesis
-
TargetJAK
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number916742-11-5
-
Formula Weight483.52
-
Molecular FormulaC23H22FN5O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (258.52 mM)
-
SMILESCCC(=O)NS(=O)(=O)c1cc(Nc2ncc(F)c(Nc3ccc(OCC#C)cc3)n2)ccc1C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
PF-06651600
PF-06651600 is a novel potent, selective JAK3 inhibitor with IC50 of 0.346 nM, displays >1,000-fold selectivity over JAK1 and JAK2; inhibits Th1 and Th17 cell differentiation and function, reduces disease pathology in rat adjuvant-induced arthritis as well as in mouse experimental autoimmune encephalomyelitis models; selectively targets γc cytokine pathways while preserving JAK1-dependent anti-inflammatory signaling such as the IL-10 suppressive functions following LPS treatment in macrophages and the suppression of TNFα and IL-1β production in IL-27-primed macrophages.Rheumatoid ArthritisPhase 2 Clinical
-
ZM39923
ZM39923 is a potent, selective JAK3 inhibitor with pIC50 of 7.1, also potently inhibits human tissue transglutaminase (TGM2) with IC50 of 10 nM.
-
PF-06700841
PF-06700841 is a potent, selective TYK2/JAK1 kinase inhibitor that reduces IL-23 expression and directly attenuates IL-23 signaling via TYK2.
